This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Agenus (AGEN) Reports Narrower-than-Expected Q2 Loss
by Zacks Equity Research
Agenus reported narrower-than-expected loss in the second quarter of 2017 but revenues missed expectations.
Sucampo (SCMP) Q2 Earnings & Revenues Beat Estimates, Up Y/Y
by Zacks Equity Research
Sucampo Pharmaceuticals' (SCMP) Amitizia recorded strong sales in Japan, which drove the company's top line. The company is also working on expanding its pipeline and Amitizia's label.
Exact Sciences Corporation (EXAS) Jumps: Stock Rises 6.2%
by Zacks Equity Research
Exact Sciences Corporation (EXAS) was a big mover last session, as the company saw its shares rise nearly 6% on the day after the company delivered yet another quarter of greater than 100% top-line growth.
What's in Store for Endocyte (ECYT) this Earnings Season?
by Zacks Equity Research
Endocyte (ECYT) looks forward to shift its focus on CAR T-cell small-molecule drug conjugates (SMDCs) adaptor platform, the dual-targeted DNA crosslinker drug EC2629 in Q2.
New Strong Buy Stocks for July 26th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
What to Expect from International Paper (IP) in Q2 Earnings?
by Zacks Equity Research
Fluctuations in actual equity market returns, changes in general interest rates are likely to hurt International Paper (IP) in Q2 earnings.
S&P Global (SPGI) to Post Q2 Earnings: A Beat in the Cards?
by Zacks Equity Research
S&P Global's (SPGI) strategic portfolio restructuring and focus on core business are expected to have a positive impact on the company's second-quarter results.
VASCO (VDSI) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Vasco's (VDSI) focus on generating high operating margins, backed by continuous investments and a shift in the product mix with higher gross-margin products, is likely to boost its Q2 earnings.
Is a Beat in Store for Agenus (AGEN) this Earnings Season?
by Zacks Equity Research
Agenus Inc. (AGEN) will focus on the development of all its pipeline drugs as currently there are no marketed drug in its portfolio.
What to Expect from Keryx (KERX) this Earnings Season?
by Zacks Equity Research
Keryx Biopharmaceuticals, Inc. (KERX) intends to focus on the growth of Auryxia in the U.S. dialysis market. The company is also making efforts for label expansion on Auryxia in the iron-deficiency anemia (IDA) indication.
Is a Beat in Store for Alexion (ALXN) this Earnings Season?
by Zacks Equity Research
Alexion Pharmaceuticals, Inc.'s (ALXN) drugs like Soliris and Strensiq have been performing well. Let's see if these lead the company to an earnings beat.
uniQure N.V. (QURE) Shows Strength: Stock Moves 9.1% Higher
by Zacks Equity Research
uniQure N.V. (QURE) was a big mover last session, as the company saw its shares rise a little above 9% on the day.
New Strong Buy Stocks for July 20th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
Agenus (AGEN) Catches Eye: Stock Moves Up 8.7% in Session
by Zacks Equity Research
Agenus Inc. (AGEN) moved big last session, as its shares rose over 8% on the day.
Eiger BioPharmaceuticals (EIGR) Rises: Stock Climbs 24%
by Zacks Equity Research
Eiger BioPharmaceuticals, Inc. (EIGR) shares rose over 24% in the last trading session.
Alexion Reportedly Being Investigated by HHS, Shares Slip
by Zacks Equity Research
Shares of Alexion Pharmaceuticals, Inc. (ALXN) were down more than 3% on Thursday after a Bloomberg report stated that it is under investigation by the U.S. Department of Health and Human Services' (HHS) Office of Inspector General (OIG).
VIVUS Settles with Teva on Weight Management Drug Generic
by Zacks Equity Research
VIVUS, Inc. (VVUS) announced that it has entered into a settlement agreement with Teva Pharmaceutical Industries Limited (TEVA), thereby resolving a three-year old patent litigation related to its weight management drug Qsymia.
Geron Stock Up Almost 40% So Far This Year After '16 Decline
by Zacks Equity Research
Geron Corporation's (GERN) shares have risen 38.7% this year so far, outperforming the Zacks classified Medical - Biomedical and Genetics industry, which rose 5.6%. This comes after a decline of more than 57% in 2016.
Is the Options Market Predicting a Spike in Agenus (AGEN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Agenus (AGEN) stock based on the movements in the options market lately.
Agenus (AGEN) Looks Good: Stock Moves Up 9.6% in Session
by Zacks Equity Research
Agenus Inc. (AGEN) moved big last session, as its shares rose almost 10% on the day.
Agenus (AGEN) Down 15.7% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Agenus (AGEN) Reports Narrower-than-Expected Loss in Q1
by Zacks Equity Research
Agenus Inc. (AGEN) reported first-quarter 2017 loss of 18 cents per share (including non-cash expenses), narrower than the Zacks Consensus Estimate of a loss of 32 cents and the year-ago loss of 37 cents.
Agenus (AGEN) Reports Narrower-than-Expected Q1 Loss
by Indrajit Bandyopadhyay
Agenus Inc. (AGEN) is a Lexington, MA-based development-stage company focused on the discovery and development of checkpoint modulators, vaccines and adjuvants for the treatment of cancer.
What's in Store for Agenus (AGEN) this Earnings Season?
by Zacks Equity Research
Agenus Inc. (AGEN) is expected to report first-quarter 2017 results later this month or early next month.
Why Is Agenus (AGEN) Down 16.8% Since the Last Earnings Report?
by Zacks Equity Research
Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.